Background: One to two percent of the population globally suffers from vitiligo, an acquired depigmentation condition of multifactorial etiology. Macules and patches of depigmentation characterize vitiligo. People's moods are affected greatly and depressingly by it. As a result, prompt and effective therapy is necessary. Many individuals are able to slow the advancement of the disease, acquire repigmentation, and achieve cosmetically appealing results with proper therapy. There is a wide range of treatments for vitiligo, including topical corticosteroids (TCS) as monotherapy (as for vitiligo local therapy) or in conjunction with phototherapy or other topical medications in generalized vitiligo.  Intermittent administration of large (pharmacological) dosages to maximize therapeutic benefit and prevent side effects is known as dexamethasone oral mini pulse (OMP) treatment. Objective: to determine the success of oral dexamethasone in vitiligo management. Conclusion: In vitiligo patients, when corticosteroids are provided at the onset or at early stages of disease, they can reduce disease progression and promote repigmentation and in some cases total repigmentation.